期刊
ANNALS OF THE RHEUMATIC DISEASES
卷 80, 期 9, 页码 1130-1136出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2020-219699
关键词
-
类别
资金
- University of Occupational and Environmental Health, Japan, through University of Occupational & Environmental Health, Japan (UOEH) for Advanced Research [19K17919]
- Grants-in-Aid for Scientific Research [19K17919] Funding Source: KAKEN
BARI demonstrated a similar safety profile and better clinical outcomes compared to TOFA after minimization of selection bias. However, these findings were based on a small population, suggesting the need for further investigation in a properly powered head-to-head trial.
Objectives The differences of efficacy between each Janus kinase (JAK) inhibitors have not been clarified in the patients with rheumatoid arthritis (RA) in clinical practice. Here, we compared the efficacy between tofacitinib (TOFA) and baricitinib (BARI) in clinical practice. Methods The efficacy of TOFA (n=156) in patients with RA was compared with BARI (n=138). Selection bias was reduced to a minimum using propensity score-based inverse probability of treatment weighting (IPTW). The Clinical Disease Activity Index (CDAI) trajectory for patients who started TOFA or BARI was analysed using growth mixture modelling (GMM). Results No significant difference was observed in patient characteristics between the TOFA and BARI groups in after adjustment by propensity score-based IPTW. The BARI group had a significantly higher rate of CDAI remission at week 24 after the introduction of JAK inhibitors than the TOFA group. The treatment-resistant group defined by GMM, comprising patients who did not achieve low disease activity at week 24, was more likely to include those who had received many biological disease-modifying antirheumatic drugs (bDMARDs) before the introduction of JAK inhibitors and those who received TOFA. Among patients with RA who received TOFA, those who had received >= 4 bDMARDs before the introduction of TOFA were more likely to be classified into the treatment-resistant group. Conclusions BARI showed a similar safety profile and better clinical outcome when compared with TOFA after reduction to a minimum of selection bias. However, these were observed in a small population. Accordingly, further investigation is required in an accurately powered head-to-head trial.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据